morphine sulfate
Drug Details
- Generic Name
- morphine sulfate
- Brand Names
- Morphine Sulfate, Morphine sulfate, INFUMORPH 500, Duramorph, MS Contin, INFUMORPH 200
- Application Number
- ANDA203158
- Sponsor
- Nortec Development Associates, Inc.
- NDC Codes
- 36
- Dosage Forms
- CAPSULE, EXTENDED RELEASE, TABLET, FILM COATED, EXTENDED RELEASE, INJECTION, SOLUTION, TABLET, INJECTION, SOLUTION
- Routes
- ORAL, EPIDURAL, INTRATHECAL, INTRAVENOUS
- Active Ingredients
- MORPHINE SULFATE
Indications and Usage
1 INDICATIONS AND USAGE Morphine sulfate extended-release tablets are indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve morphine sulfate extended-release for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. Morphine sulfate extended-release is an opioid agonist indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. (1) Limitations of Use (1) Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations, reserve morphine sulfate extended-release for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic.